Verano Holdings VRNO
OTC VRNO
$6.09 +0.25 (+4.28%)
At close: Aug 19, 2026 · 3:58 PM UTC

Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026)

Verano Holdings (VRNO) posted quarterly Total Non-Current Liabilities of $902.9 million for Q1 2026, up 5.02% year-over-year from $859.7 million in Q1 2025, and little changed quarter-over-quarter from $899.0 million in Q4 2025.

Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has reported Total Non-Current Liabilities for 6 consecutive years, with $902.9 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 5.02% year-over-year to $902.9 million; the TTM figure through Mar 2026 stood at $902.9 million (up 5.02% YoY), while the FY2025 annual figure was $899.0 million, up 7.0% from the prior year.
  • Total Non-Current Liabilities steadied at $902.9 million in Q1 2026 per VRNO's latest filing, from $899.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $902.9 million in Q1 2026 and bottomed at $469.5 million in Q2 2022.
  • Historically, Total Non-Current Liabilities has averaged $736.3 million across 5 years, with a median of $680.7 million in 2023.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 43.17% — and 2024, when it slipped 4.02%.
  • Verano Holdings' Total Non-Current Liabilities stood at $667.9 million in 2022, then slipped by 0.21% to $666.5 million in 2023, then increased by 26.06% to $840.2 million in 2024, then increased by 7.0% to $899.0 million in 2025, then rose by 0.44% to $902.9 million in 2026.
  • Business Quant data shows VRNO's Total Non-Current Liabilities at $902.9 million in Q1 2026, $899.0 million in Q4 2025, and $897.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 43.98 Bn 43.02 Bn - -13.28 Bn
2 Teva Pharmaceutical Industries 43.28 Bn 39.62 Bn 2.15 Bn 16.45 Bn
3 Zoetis 31.79 Bn 30.11 Bn 1.05 Bn 11.64 Bn
4 Takeda Pharmaceutical 28.69 Bn 22.89 Bn 5.10 Bn 33.50 Bn
5 United Therapeutics 22.25 Bn 19.58 Bn 683.80 Mn 607.80 Mn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn 18.76 Bn
7 Neurocrine Biosciences 15.58 Bn 15.19 Bn 935.80 Mn 1.37 Bn
8 Elanco Animal Health 11.87 Bn 11.34 Bn 798.00 Mn 6.42 Bn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - 334.00 Mn
10 Verano Holdings 440.28 Mn 355.08 Mn 99.70 Mn 915.16 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 915.16 Mn
Mar 31, 2026 902.87 Mn
Dec 31, 2025 898.95 Mn
Sep 30, 2025 897.85 Mn
Jun 30, 2025 868.42 Mn
Mar 31, 2025 859.73 Mn
Dec 31, 2024 840.17 Mn
Sep 30, 2024 661.59 Mn
Jun 30, 2024 657.07 Mn
Mar 31, 2024 661.13 Mn
Dec 31, 2023 666.48 Mn
Sep 30, 2023 689.32 Mn
Jun 30, 2023 672.14 Mn
Mar 31, 2023 669.11 Mn
Dec 31, 2022 667.86 Mn
Sep 30, 2022 698.54 Mn
Jun 30, 2022 469.47 Mn
Dec 31, 2021 596.33 Mn